Bone marrow transplant breakthrough: more donors now possible for blood cancer patients?
NCT ID NCT01203722
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested a gentler bone marrow transplant for people with blood cancers who don't have a perfectly matched family donor. Instead, it used donors who are less closely matched, like unrelated volunteers or distant relatives. The goal was to see if this approach could be safe and effective, reducing severe side effects like graft-versus-host disease while helping patients survive longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fludarabine, Cytoxan, Sirolimus, Mycophenolate Mofetil, total body irradiation, and allogeneic blood or marrow transplant
What this could lead to
If successful, this approach could expand donor options for blood cancer patients who lack a matched family donor, potentially improving access to life-saving transplants.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 87 participants, so results may not apply to all patients. Risks include severe graft-versus-host disease, infection, and transplant failure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231-2410, United States